Clinical Cancer Research, Vol 2, Issue 3 483-491, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

A Thibault, D Samid, AC Tompkins, WD Figg, MR Cooper, RJ Hohl, J Trepel, B Liang, N Patronas, DJ Venzon, E Reed and CE Myers
Clinical Pharmacology Branch and Biometrics Section, National Cancer Institute, Warren Magnussen Clinical Center, NIH, Bethesda, Maryland 20892-1576, USA.

Lovastatin, an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (the major regulatory enzyme of the mevalonate pathway of cholesterol synthesis), displays antitumor activity in experimental models. We therefore conducted a Phase I trial to characterize the tolerability of lovastatin administered at progressively higher doses to cancer patients. From January 1992 to July 1994, 88 patients with solid tumors (median age, 57 +/- 14 years) were treated p.o. with 7-day courses of lovastatin given monthly at doses ranging from 2 to 45 mg/kg/day. The inhibitory effects of lovastatin were monitored through serum concentrations of cholesterol and ubiquinone, two end products of the mevalonate pathway. Concentrations of lovastatin and its active metabolites were also determined, by bioassay, in the serum of selected patients. Cyclical treatment with lovastatin markedly inhibited the mevalonate pathway, evidenced by reductions in both cholesterol and ubiquinone concentrations, by up to 43 and 49% of pretreatment values, respectively. The effect was transient, however, and its magnitude appeared to be dose independent. Drug concentrations reached up to 3.9 micrometer and were in the range associated with antiproliferative activity in vitro. Myopathy was the dose-limiting toxicity. Other toxicities included nausea, diarrhea, and fatigue. Treatment with ubiquinone was associated with reversal of lovastatin-induced myopathy, and its prophylactic administration prevented the development of this toxicity in a cohort of 56 patients. One minor response was documented in a patient with recurrent high-grade glioma. Lovastatin given p.o. at a dose of 25 mg/kg daily for 7 consecutive days is well tolerated. The occurrence of myopathy, the dose-limiting toxicity, can be prevented by ubiquinone supplementation. To improve on the transient inhibitory activity of this dosing regimen on the mevalonate pathway, alternative schedules based on uninterrupted administration of lovastatin should also be studied.

This article has been cited by other articles:

				J. W. Wojtkowiak, F. Fouad, D. T. LaLonde, M. D. Kleinman, R. A. Gibbs, J. J. Reiners Jr., R. F. Borch, and R. R. Mattingly Induction of Apoptosis in Neurofibromatosis Type 1 Malignant Peripheral Nerve Sheath Tumor Cell Lines by a Combination of Novel Farnesyl Transferase Inhibitors and Lovastatin J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 1 - 11. [Abstract] [Full Text] [PDF]

				O. Fromigue, Z. Hamidouche, and P. J. Marie Statin-Induced Inhibition of 3-Hydroxy-3-Methyl Glutaryl Coenzyme A Reductase Sensitizes Human Osteosarcoma Cells to Anticancer Drugs J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 595 - 600. [Abstract] [Full Text] [PDF]

				E. van der Spek, A.C. Bloem, H.A. Sinnige, and H.M. Lokhorst High dose Simvastatin does not reverse resistance to Vincristine, Adriamycin, and Dexamethasone (VAD) in Myeloma Haematologica, December 1, 2007; 92(12): e130 - e131. [Abstract] [Full Text] [PDF]

				N. Niknejad, M. Morley, and J. Dimitroulakos Activation of the Integrated Stress Response Regulates Lovastatin-induced Apoptosis J. Biol. Chem., October 12, 2007; 282(41): 29748 - 29756. [Abstract] [Full Text] [PDF]

				S. Kotamraju, C. L. Willams, and B. Kalyanaraman Statin-Induced Breast Cancer Cell Death: Role of Inducible Nitric Oxide and Arginase-Dependent Pathways Cancer Res., August 1, 2007; 67(15): 7386 - 7394. [Abstract] [Full Text] [PDF]

				R. Kaneko, N. Tsuji, K. Asanuma, H. Tanabe, D. Kobayashi, and N. Watanabe Survivin Down-regulation Plays a Crucial Role in 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor-induced Apoptosis in Cancer J. Biol. Chem., July 6, 2007; 282(27): 19273 - 19281. [Abstract] [Full Text] [PDF]

				A. J. Roelofs, C. M. Edwards, R. G. G. Russell, F. H. Ebetino, M. J. Rogers, and P. A. Hulley Apomine Enhances the Antitumor Effects of Lovastatin on Myeloma Cells by Down-Regulating 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 228 - 235. [Abstract] [Full Text] [PDF]

				L. Marcoff and P. D. Thompson The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2231 - 2237. [Abstract] [Full Text] [PDF]

				W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma Mol. Cancer Ther., June 1, 2007; 6(6): 1886 - 1897. [Abstract] [Full Text] [PDF]

				V. Khurana, H. R. Bejjanki, G. Caldito, and M. W. Owens Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans Chest, May 1, 2007; 131(5): 1282 - 1288. [Abstract] [Full Text] [PDF]

				B. von Tresckow, E. P. von Strandmann, S. Sasse, S. Tawadros, A. Engert, and H. P. Hansen Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo Haematologica, May 1, 2007; 92(5): 682 - 685. [Abstract] [Full Text] [PDF]

				J. A. McAnally, J. Gupta, S. Sodhani, L. Bravo, and H. Mo Tocotrienols Potentiate Lovastatin-Mediated Growth Suppression In Vitro and In Vivo Experimental Biology and Medicine, April 1, 2007; 232(4): 523 - 531. [Abstract] [Full Text] [PDF]

				S. M. Kornblau, D. E. Banker, D. Stirewalt, D. Shen, E. Lemker, S. Verstovsek, Z. Estrov, S. Faderl, J. Cortes, M. Beran, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study Blood, April 1, 2007; 109(7): 2999 - 3006. [Abstract] [Full Text] [PDF]

				A. Yacoub, W. Hawkins, D. Hanna, H. Young, M. A. Park, M. Grant, J. D. Roberts, D. T. Curiel, P. B. Fisher, K. Valerie, et al. Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment Mol. Pharmacol., January 1, 2007; 71(1): 259 - 275. [Abstract] [Full Text] [PDF]

				S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, and R. P. Dellavalle Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. J Natl Cancer Inst, November 1, 2006; 98(21): 1538 - 1546. [Abstract] [Full Text] [PDF]

				U. Sivaprasad, T. Abbas, and A. Dutta Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2310 - 2316. [Abstract] [Full Text] [PDF]

				J. Dimitroulakos, I. A. Lorimer, and G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin. Cancer Res., July 15, 2006; 12(14): 4426s - 4431s. [Abstract] [Full Text] [PDF]

				K. Morimoto, W. J. Janssen, M. B. Fessler, K. A. McPhillips, V. M. Borges, R. P. Bowler, Y.-Q. Xiao, J. A. Kench, P. M. Henson, and R. W. Vandivier Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J. Immunol., June 15, 2006; 176(12): 7657 - 7665. [Abstract] [Full Text] [PDF]

				T. Nubel, J. Damrot, W. P. Roos, B. Kaina, and G. Fritz Lovastatin Protects Human Endothelial Cells from Killing by Ionizing Radiation without Impairing Induction and Repair of DNA Double-Strand Breaks Clin. Cancer Res., February 1, 2006; 12(3): 933 - 939. [Abstract] [Full Text] [PDF]

				K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]

				W-B Zhong, Y-C Liang, C-Y Wang, T-C Chang, and W-S Lee Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling Endocr. Relat. Cancer, September 1, 2005; 12(3): 615 - 629. [Abstract] [Full Text] [PDF]

				J. Sacher, L. Weigl, M. Werner, C. Szegedi, and M. Hohenegger Delineation of Myotoxicity Induced by 3-Hydroxy-3-methylglutaryl CoA Reductase Inhibitors in Human Skeletal Muscle Cells J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1032 - 1041. [Abstract] [Full Text] [PDF]

				P. N. Kao Simvastatin Treatment of Pulmonary Hypertension: An Observational Case Series Chest, April 1, 2005; 127(4): 1446 - 1452. [Abstract] [Full Text] [PDF]

				A. J. Mantha, J. E.L. Hanson, G. Goss, A. E. Lagarde, I. A. Lorimer, and J. Dimitroulakos Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor Clin. Cancer Res., March 15, 2005; 11(6): 2398 - 2407. [Abstract] [Full Text] [PDF]

				A. Horiguchi, M. Sumitomo, J. Asakuma, T. Asano, T. Asano, and M. Hayakawa 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis Clin. Cancer Res., December 15, 2004; 10(24): 8648 - 8655. [Abstract] [Full Text] [PDF]

				L. Roffe, K. Schmidt, and E. Ernst Efficacy of Coenzyme Q10 for Improved Tolerability of Cancer Treatments: A Systematic Review J. Clin. Oncol., November 1, 2004; 22(21): 4418 - 4424. [Abstract] [Full Text] [PDF]

				M.-A. Shibata, Y. Ito, J. Morimoto, and Y. Otsuki Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism Carcinogenesis, October 1, 2004; 25(10): 1887 - 1898. [Abstract] [Full Text] [PDF]

				J. Wu, W. W.-L. Wong, F. Khosravi, M. D. Minden, and L. Z. Penn Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis Cancer Res., September 15, 2004; 64(18): 6461 - 6468. [Abstract] [Full Text] [PDF]

				D. E. Banker, S. J. Mayer, H. Y. Li, C. L. Willman, F. R. Appelbaum, and R. A. Zager Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells Blood, September 15, 2004; 104(6): 1816 - 1824. [Abstract] [Full Text] [PDF]

				H. Mo and C. E. Elson Studies of the Isoprenoid-Mediated Inhibition of Mevalonate Synthesis Applied to Cancer Chemotherapy and Chemoprevention Experimental Biology and Medicine, July 1, 2004; 229(7): 567 - 585. [Abstract] [Full Text] [PDF]

				M. R. Graaf, A. B. Beiderbeck, A. C.G. Egberts, D. J. Richel, and H.-J. Guchelaar The Risk of Cancer in Users of Statins J. Clin. Oncol., June 15, 2004; 22(12): 2388 - 2394. [Abstract] [Full Text] [PDF]

				H. Katano, L. Pesnicak, and J. I. Cohen Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas PNAS, April 6, 2004; 101(14): 4960 - 4965. [Abstract] [Full Text] [PDF]

				N. W. C. J. van de Donk, D. Schotte, M. M. J. Kamphuis, A. M. W. van Marion, B. van Kessel, A. C. Bloem, and H. M. Lokhorst Protein Geranylgeranylation Is Critical for the Regulation of Survival and Proliferation of Lymphoma Tumor Cells Clin. Cancer Res., November 15, 2003; 9(15): 5735 - 5748. [Abstract] [Full Text] [PDF]

				W.-B. Zhong, C.-Y. Wang, T.-C. Chang, and W.-S. Lee Lovastatin Induces Apoptosis of Anaplastic Thyroid Cancer Cells via Inhibition of Protein Geranylgeranylation and de Novo Protein Synthesis Endocrinology, September 1, 2003; 144(9): 3852 - 3859. [Abstract] [Full Text] [PDF]

				H. Y. Li, F. R. Appelbaum, C. L. Willman, R. A. Zager, and D. E. Banker Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses Blood, May 1, 2003; 101(9): 3628 - 3634. [Abstract] [Full Text] [PDF]

				A. B. Beiderbeck, E. A. Holly, M. C. J. M. Sturkenboom, J. W. W. Coebergh, B. H. Ch. Stricker, and H. G. M. Leufkens Prescription Medications Associated with a Decreased Risk of Non-Hodgkin's Lymphoma Am. J. Epidemiol., March 15, 2003; 157(6): 510 - 516. [Abstract] [Full Text] [PDF]

				K. K. W. Chan, A. M. Oza, and L. L. Siu The Statins as Anticancer Agents Clin. Cancer Res., January 1, 2003; 9(1): 10 - 19. [Abstract] [Full Text] [PDF]

				S. A. Holstein and R. J. Hohl Synergistic Interaction of Lovastatin and Paclitaxel in Human Cancer Cells Mol. Cancer Ther., December 1, 2001; 1(2): 141 - 149. [Abstract] [Full Text] [PDF]

				A. A. Adjei Blocking Oncogenic Ras Signaling for Cancer Therapy J Natl Cancer Inst, July 18, 2001; 93(14): 1062 - 1074. [Abstract] [Full Text] [PDF]

				W. W.-L. Wong, M. M. Tan, Z. Xia, J. Dimitroulakos, M. D. Minden, and L. Z. Penn Cerivastatin Triggers Tumor-specific Apoptosis with Higher Efficacy than Lovastatin Clin. Cancer Res., July 1, 2001; 7(7): 2067 - 2075. [Abstract] [Full Text] [PDF]

				T. Kusama, M. Mukai, T. Iwasaki, M. Tatsuta, Y. Matsumoto, H. Akedo, and H. Nakamura Inhibition of Epidermal Growth Factor-induced RhoA Translocation and Invasion of Human Pancreatic Cancer Cells by 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors Cancer Res., June 1, 2001; 61(12): 4885 - 4891. [Abstract] [Full Text] [PDF]

				J. Dimitroulakos, L. Y. Ye, M. Benzaquen, M. J. Moore, S. Kamel-Reid, M. H. Freedman, H. Yeger, and L. Z. Penn Differential Sensitivity of Various Pediatric Cancers and Squamous Cell Carcinomas to Lovastatin-induced Apoptosis: Therapeutic Implications Clin. Cancer Res., January 1, 2001; 7(1): 158 - 167. [Abstract] [Full Text]

				W. Feleszko, I. Mlynarczuk, E. Z. Balkowiec-Iskra, A. Czajka, T. Switaj, T. Stoklosa, A. Giermasz, and M. Jakóbisiak Lovastatin Potentiates Antitumor Activity and Attenuates Cardiotoxicity of Doxorubicin in Three Tumor Models in Mice Clin. Cancer Res., May 1, 2000; 6(5): 2044 - 2052. [Abstract] [Full Text]

				A. Faggiotto and R. Paoletti Statins and Blockers of the Renin-Angiotensin System : Vascular Protection Beyond Their Primary Mode of Action Hypertension, October 1, 1999; 34(4): 987 - 996. [Abstract] [Full Text] [PDF]

				R. H. WEISS, A. RAMIREZ, and A. JOO Short-Term Pravastatin Mediates Growth Inhibition and Apoptosis, Independently of Ras, via the Signaling Proteins p27Kip1 and PI3 Kinase J. Am. Soc. Nephrol., September 1, 1999; 10(9): 1880 - 1890. [Abstract] [Full Text]

				J. Dimitroulakos, D. Nohynek, K. L. Backway, D. W. Hedley, H. Yeger, M. H. Freedman, M. D. Minden, and L. Z. Penn Increased Sensitivity of Acute Myeloid Leukemias to Lovastatin-Induced Apoptosis: A Potential Therapeutic Approach Blood, February 15, 1999; 93(4): 1308 - 1318. [Abstract] [Full Text] [PDF]

				S. J. Lee, M. J. Ha, J. Lee, P. Nguyen, Y. H. Choi, F. Pirnia, W.-K. Kang, X.-F. Wang, S.-J. Kim, and J. B. Trepel Inhibition of the 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Pathway Induces p53-independent Transcriptional Regulation of p21WAF1/CIP1 in Human Prostate Carcinoma Cells J. Biol. Chem., April 24, 1998; 273(17): 10618 - 10623. [Abstract] [Full Text] [PDF]

				L. He, H. Mo, S. Hadisusilo, A. A. Qureshi, and C. E. Elson Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo J. Nutr., May 1, 1997; 127(5): 668 - 674. [Abstract] [Full Text] [PDF]